CRISPR and Cas Genes Market Trends

Growth Drivers

• Rising focus and investments in genomic therapy: As the demand for personalized medicine rises, investments in the CRISPR & cas genes market inflate. Many research-based pharmaceutical companies and public health authorities are now developing interest in this field to gain the ability to customize and enhance the genetic profiles and specificity of drugs. For instance, in July 2023, researchers from Duke University and the University of California San Diego introduced two different CRISPR-based therapeutic pathways, APOE-e4 and beta-amyloid, for treating Alzheimer's. Great improvements in outcomes were displayed at the Alzheimer’s Association International Conference, held in Amsterdam, Netherlands, encouraging others to work in this category.    
• Advancements in genetic editing technologies: The contribution of gene editing technologies in the escalation of the understanding of heterogeneity in certain medical conditions is influencing MedTech pioneers to develop new platforms and tools. These tech-based laboratory solutions further leverage the quality and efficacy of products from the CRISPR & cas genes market. On this note, in January 2022, Bayer AG paid USD 40.0 million upfront cash to Mammoth Biosciences for accessing its novel CRISPR systems to produce in vivo gene-editing therapies.

Challenges

• Limitations in drug delivery systems: Finding the right method or carrier for the components, induced by the researchers associated with the CRISPR & cas genes market, is still a challenge. In-efficiency of existing solutions, such as viral vectors and nanoparticles, often causes delays and safety concerns. The absence of appropriate systems may also result in unintended genetic modifications, harming mutational properties and immune response. These factors may create barriers against the exponential growth of this field.
• High competency and volatility: There is a risk of fostering legal disputes and uncertainty on proprietorship of intellectual properties due to the highly competitive landscape of the CRISPR & cas genes market. The ongoing battles between biotech companies and research institutions in advancing may develop a hard-to-concur environment for newcomers. This further restricts diversity in this field, limiting productivity and frequency of discoveries. Moreover, the disparities in supply and distribution channels may hinder availability and market expansion.